Insulin resistance impairs viral dynamics independently of ethnicity or genotypes

Journal of Clinical Gastroenterology

Volumn 46, Issue 3, 2012, Pages 228-234

  Eslam, Mohammed ^a,b   Aparcero, Reyes ^a   Mousa, Youssef I ^b   Grande, Lourdes ^a   Shaker, Yehia ^b   Ali, Ahmed ^a   Del Campo, José A ^a   Khattab, Mahmoud A ^b   Romero Gomez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b MINIA UNIVERSITY   (Egypt)

Author keywords

hepatitis c virus; HOMA IR; insulin resistance; viral dynamics

Indexed keywords

INSULIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; EGYPT; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPONSE TIME; SCORING SYSTEM; SPAIN; VIRUS GENE; VIRUS LOAD; VIRUS VIABILITY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOSPITALS, UNIVERSITY; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857049218     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31822a2dc6     Document Type: Article

References (33)

1. World health organization. Hepatitis C. Fact sheet number 164, revised October 2000. http://www.who.int/mediacentre/facts sheets/fs164len, accessed March 6, 2009.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(Suppl. 1):S35-S46. (Pubitemid 35253462)
3. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
4. Farrell GC. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22L:615-633.
5. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon a-2a and ribavirin. Hepatology. 2008;48:1033-1043.
6. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;15:257-276.
7. Zeuzem S. Heterogeneous virologic response rates to interferon- based therapy in patients with chronic hepatitis C: who respond less well ? Ann Intern Med. 2004;140:370-381. (Pubitemid 38268917)
8. O'Brien TR. Interferon-alfa, interferon-l and hepatitis C. Nat Genet. 2009;41:1048-1050.
9. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641. (Pubitemid 40585366)
10. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48:28-34. (Pubitemid 350191982)
11. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712-718.
12. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to Peginterferon/Ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970-1977.
13. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology. 2006;43:954-960. (Pubitemid 43724620)
14. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology. 2007;46:1732-1740.
15. Shudo E, Ribeiro RM, Talal AH, et al. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther. 2008;13:919-926.
16. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;5(Suppl. 1):S145-S151. (Pubitemid 35253475)
17. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358. (Pubitemid 36667315)
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27no(suppl 1):s5-s10.
19. World Health Organization 2000 Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva: World Health Organization; 2000.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293. (Pubitemid 26260021)
21. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297-305.
22. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes. 1989;38:641-647. (Pubitemid 19125614)
23. Imano E, Kanda T, Ishigami Y, et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol. 1998;28:189-193. (Pubitemid 28116425)
24. Franceschini L, Marcolongo M, Bortoletto G, et al. A noncanonical interferon-alpha pathway, through IRS1, might be involved in the reduced antiviral therapy response in patients with insulin resistance and chronic hepatitis C. J Hepatol. 2009;50(Suppl. 1):321.
25. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. 2006; 43:1168; author reply 1168-1169.
26. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virologic response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51:984-990.
27. Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virological response in HIV/ hepatitis C virus coinfected patients on peginterferon-alpha-2a. AIDS. 2008;22: 857-861. (Pubitemid 351563835)
28. Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology. 2010;52:38-46.
29. Elgouhari HM, Cesario KB, Lopez R, et al. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts. Hepatology. 2008;48:383A.
30. Conjeevaram H, Burant CF, McKenna B, et al. A randomized, double-blind, placebo-controlled study of PPAR gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1chronic hepatitis C. Hepatology. 2008;48:384A.
31. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010;30:447-454.
32. Vierling JM, Prbhaker A, Han J, et al. Virologic and metabolic responses in chronic hepatitis C (CHC) patients with insulin resistance (IR) treated with pioglitazone and peginterferon alpha-2 A plus ribavirin. Final results of week 12 early virologic response. Hepatology. 2010;52:707A.
33. Romero-Gómez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009;50:1702-1708.